Genero Pharmaceuticals is primarily engaged in pharmaceutical preparations activity. Its headquarters is located in Dki Jakarta. The company was founded in 2000. Founded by Dr. Arif Rahman, Genero Pharmaceuticals has established itself as a key player in the Indonesian pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and health supplements. Genero Pharmaceuticals operates several branches across Indonesia, with a strong presence in major cities such as Surabaya, Bandung, and Medan. The company has also expanded its operations internationally, exporting its products to several countries in Southeast Asia and beyond. The company's product portfolio includes well-known brands such as GenMed, a line of generic medications, and VitaPlus, a range of health supplements. Genero Pharmaceuticals is committed to innovation and quality, investing heavily in research and development to bring new and effective treatments to market. In addition to its core pharmaceutical business, Genero Pharmaceuticals has formed strategic partnerships with international pharmaceutical companies to enhance its product offerings and expand its market reach. The company is a member of the Indonesian Pharmaceutical Association and actively participates in industry events and forums. Genero Pharmaceuticals is dedicated to improving public health and well-being, with a mission to provide affordable and accessible healthcare solutions. The company's vision is to become a leading pharmaceutical company in Asia, known for its commitment to quality, innovation, and customer satisfaction.
Headquarters
District 8, Sudirman Central Business District (SCBD) Lot 28
South Jakarta; Jakarta;
Postal Code: 12190
Contact Details: Purchase the PT Genero Pharmaceuticals report to view the information.
Website: http://www.genero.co.id
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service